Literature DB >> 16616891

A dominant negative form of p63 inhibits apoptosis in a p53-independent manner.

Hae-ock Lee1, Jung-Hwa Lee, Eunhee Choi, Ja Young Seol, Yungdae Yun, Hyunsook Lee.   

Abstract

Stem cells are a source of differentiated cells in multiple tissues. If genetic alterations occur in stem cells, the problem persists and malignant cancers may arise. DeltaNp63alpha-a homologue of the tumor suppressor p53-is exclusively expressed in proliferating undifferentiated epithelial cells and cancer cells of epidermal origin. Here, we show that DeltaNp63alpha antagonizes DNA damage-induced apoptosis in a p53-independent manner. We found that upon cellular injury, DeltaNp63alpha must be downregulated before apoptotic program can be activated. The 5637 cell line has abundant levels of DeltaNp63alpha and mutant p53, and it is resistant to DNA damage-induced apoptosis. The knockdown of DeltaNp63alpha by RNA interference sensitized these cells to apoptosis upon genotoxic insult. This suggests that DeltaNp63alpha plays an anti-apoptotic role regardless of the p53 status. Considering the frequent mutations of p53 in tumor cells, our results provide important implications for the treatment of cancers in which p63 is amplified.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616891     DOI: 10.1016/j.bbrc.2006.03.128

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation.

Authors:  Yingchun Li; Melissa J Peart; Carol Prives
Journal:  Mol Cell Biol       Date:  2009-05-18       Impact factor: 4.272

2.  C-terminal cleavage of DeltaNp63alpha is associated with TSA-induced apoptosis in immortalized corneal epithelial cells.

Authors:  Danielle M Robertson; Su-Inn Ho; H Dwight Cavanagh
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

3.  Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis.

Authors:  Andrea Arenz; Frank Ziemann; Christina Mayer; Andrea Wittig; Kirstin Dreffke; Stefanie Preising; Steffen Wagner; Jens-Peter Klussmann; Rita Engenhart-Cabillic; Claus Wittekindt
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

4.  p63 short isoforms are found in invasive carcinomas only and not in benign breast conditions.

Authors:  Dario de Biase; Luca Morandi; Roberta Degli Esposti; Claudia Ligorio; Annalisa Pession; Maria P Foschini; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2010-03-12       Impact factor: 4.064

5.  Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63.

Authors:  Bridget E Ferguson-Yates; Hongyan Li; Tiffany K Dong; Jennifer L Hsiao; Dennis H Oh
Journal:  Carcinogenesis       Date:  2007-11-04       Impact factor: 4.944

Review 6.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

7.  Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer.

Authors:  Shahin Assefnia; Keunsoo Kang; Svenja Groeneveld; Daisuke Yamaji; Sarah Dabydeen; Ahmad Alamri; Xuefeng Liu; Lothar Hennighausen; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

8.  Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation.

Authors:  Raúl González; Ángel J De la Rosa; Alessandro Rufini; María A Rodríguez-Hernández; Elena Navarro-Villarán; Trinidad Marchal; Sheila Pereira; Manuel De la Mata; Martina Müller-Schilling; Juan M Pascasio-Acevedo; María T Ferrer-Ríos; Miguel A Gómez-Bravo; Francisco J Padillo; Jordi Muntané
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

9.  Identification of an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk.

Authors:  Aleksandra M Dudek; Sita H Vermeulen; Dimitar Kolev; Anne J Grotenhuis; Lambertus A L M Kiemeney; Gerald W Verhaegh
Journal:  Cell Oncol (Dordr)       Date:  2018-06-28       Impact factor: 6.730

10.  Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma.

Authors:  Masakazu Yoshida; Etsuko Yokota; Tetsushi Sakuma; Tomoki Yamatsuji; Nagio Takigawa; Toshikazu Ushijima; Takashi Yamamoto; Takuya Fukazawa; Yoshio Naomoto
Journal:  Oncotarget       Date:  2018-06-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.